SUPRATARSAL INJECTION OF TRIAMCINOLONE ACETONIDE FOR THE TREATMENT OF SEVERE VERNAL KERATOCONJUNCTIVITIS
Objective: To find out the use of supratarsal injection of triamcinolone acetonide in severe vernal keratoconjunctivitis in children.
Methodology: This descriptive study was conducted at Department of Ophthalmology, Hayatabad Medical Complex (HMC), Peshawar from 1st May, 2015 to 30th September, 2016. It included 62 eyes of 39 patients with severe vernal keratoconjunctivitis (VKC) associated with shield ulceration/keratitis, gelatinous limbal infiltrate and/or giant papillae on tarsal conjunctiva which showed resistance to conventional topical anti-allergic drops. Patients were treated with 20mg (0.5ml) supratarsal injection of triamcinolone acetonide. The patients were followed at 1st, 2nd and 4th weeks and at 3rd and 4th months after injection. Data analysis were done using SPSS version 16.
Results: Our study included 62 eyes of 39 patients. Twenty two (56.41%) patients were male and 17(43.59%) were females. Mean age was 6.90 years (range 4.0-10 years). In all patients (100%), the disease was successfully controlled for an average of 3 months. Repeat injection was needed in 4 patients (10.26%) at one month post injection due to early recurrence of symptoms & signs. Only 9 (23.07%) patients required repeat injection after 3 months. We observed no intraoperative or postoperative complications like cataract and glaucoma.
Conclusion: Rapid and dramatic clinical response and lack of complications suggested that supratarsal injection of triamcinolone acetonide constitutes an effective and safe option for severe and challenging cases of vernal keratoconjunctivitis.
- There are currently no refbacks.